Neurocrine Biosciences
NBIX • NASDAQ
Neurocrine Biosciences is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Kyle W. Gano, with a market cap of $12.9B.
CEOKyle W. Gano
Market Cap$12.9B
Drug Manufacturers - Specialty & Generic
Healthcare
Employees1.4K
Websiteneurocrine.com
Next Earnings
Upcoming earnings announcement for Neurocrine Biosciences
Date
Monday, May 4, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.54
Revenue Estimate
$755.6M
Earnings History
Past 12 earnings reports for Neurocrine Biosciences
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | Q4 2025 | $1.88Est: $2.09 | -10.0% | $805.5MEst: $786.7M | +2.4% | — |
| Oct 28, 2025 | Q3 2025 | $2.17Est: $1.87 | +16.0% | $794.9MEst: $745.8M | +6.6% |  10-Q |
| Jul 30, 2025 | Q2 2025 | $1.65Est: $1.27 | +29.9% | $687.5MEst: $651.2M | +5.6% | 10-Q |
| May 5, 2025 | Q1 2025 | $0.70Est: $1.09 | -35.8% | $572.6MEst: $561.0M | +2.1% | 10-Q |
| Feb 6, 2025 | Q4 2024 | $1.69Est: $1.71 | -1.2% | $627.7MEst: $629.0M | -0.2% | 10-K |
| Oct 30, 2024 | Q3 2024 | $1.81Est: $1.51 | +19.9% | $622.1MEst: $600.6M | +3.6% | 10-Q |
| Aug 1, 2024 | Q2 2024 | $1.63Est: $1.03 | +58.3% | $590.2MEst: $547.1M | +7.9% | 10-Q |
| May 1, 2024 | Q1 2024 | $1.20Est: $1.01 | +18.8% | $515.3MEst: $512.0M | +0.7% | 10-Q |
| Feb 7, 2024 | Q4 2023 | $1.54Est: $1.15 | +33.9% | $515.2MEst: $518.1M | -0.6% | 10-K |
| Oct 31, 2023 | Q3 2023 | $1.54Est: $0.98 | +57.1% | $498.8MEst: $469.9M | +6.1% | — |
| Aug 1, 2023 | Q2 2023 | $1.25Est: $0.77 | +62.3% | $452.7MEst: $448.9M | +0.8% | 10-Q |
| May 3, 2023 | Q1 2023 | -$0.51Est: $0.13 | -492.3% | $420.4MEst: $409.4M | +2.7% | 10-Q |